Anixa Biosciences, Inc. (ANIX) Stock Price

ANIXStock

$2.67−39.32%52W

Market Cap$92.82M

P/E—

PEG Ratio-0.11

Div yield—

Beta0.48

ANIX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-17.20%

Price vs S&P 500 (4W)0.21%

PEG Ratio-0.11

VGM Score34.10

Book Value / Share (Quarterly)$0.42

P/TBV (Annual)14.95x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.21

Price vs S&P 500 (YTD)-26.35%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-1090.48%

EPS (TTM)$-0.31

10-Day Avg Trading Volume0.23M

EPS Excl Extra (TTM)$-0.31

EPS (Annual)$-0.34

ROI (Annual)-72.07%

Gross Margin (Annual)97.00%

Net Profit Margin (5Y Avg)-2904.81%

Cash / Share (Quarterly)$0.40

ROA (Last FY)-67.95%

EBITD / Share (TTM)$-0.33

ROE (5Y Avg)-51.70%

Operating Margin (TTM)-1219.05%

Cash Flow / Share (Annual)$-0.22

P/B Ratio6.41x

P/B Ratio (Quarterly)8.04x

Net Income / Employee (Annual)$-2,731,700

EV / Revenue (TTM)435.34x

Net Interest Coverage (TTM)-9.44x

ROA (TTM)-67.80%

EPS Incl Extra (Annual)$-0.34

Current Ratio (Annual)8.08x

Quick Ratio (Quarterly)7.95x

3-Month Avg Trading Volume0.29M

52-Week Price Return-39.32%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.26

P/S Ratio (Annual)442.00x

Asset Turnover (Annual)0.01x

52-Week High$5.46

Operating Margin (5Y Avg)-3024.30%

EPS Excl Extra (Annual)$-0.34

Tangible BV CAGR (5Y)36.29%

26-Week Price Return-7.29%

Quick Ratio (Annual)7.71x

13-Week Price Return-21.47%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)8.54x

Enterprise Value$91.42M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)4.92%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)0.45x

Pretax Margin (Annual)-4728.57%

Cash / Share (Annual)$0.46

3-Month Return Std Dev53.00%

Gross Margin (5Y Avg)88.48%

Net Income / Employee (TTM)$-2,595,500

ROE (Last FY)-72.07%

Net Interest Coverage (Annual)-9.44x

EPS Basic Excl Extra (Annual)$-0.34

P/FCF (TTM)20.18x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.31

Receivables Turnover (Annual)0.00x

ROI (TTM)-70.17%

P/S Ratio (TTM)442.00x

Pretax Margin (5Y Avg)-2941.13%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.26

Price vs S&P 500 (52W)-54.85%

Year-to-Date Return-14.42%

5-Day Price Return-5.99%

EPS Normalized (Annual)$-0.34

ROA (5Y Avg)-48.99%

Net Profit Margin (Annual)-4671.90%

Month-to-Date Return-8.87%

EBITD / Share (Annual)$-0.36

Operating Margin (Annual)-5243.33%

LT Debt / Equity (Annual)4.72x

ROI (5Y Avg)-51.70%

LT Debt / Equity (Quarterly)11.73x

EPS Basic Excl Extra (TTM)$-0.31

P/TBV (Quarterly)14.95x

P/B Ratio (Annual)8.97x

Inventory Turnover (TTM)0.89x

Pretax Margin (TTM)-1100.00%

Book Value / Share (Annual)$0.46

Price vs S&P 500 (13W)-24.16%

Beta0.48x

P/FCF (Annual)70.85x

Revenue / Share (TTM)$0.00

ROE (TTM)-70.17%

52-Week Low$2.32

vGradeF

mGradeC

vgmGradeD

ANIX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Sep 9, 2026	-$0.08	-$0.08	+0.00%(+$0.00)
Q1 2026	Jun 10, 2026	-$0.10	-$0.07	+30.00%(+$0.03)
Q4 2025	Mar 9, 2026	-$0.09	-$0.08	+11.11%(+$0.01)
Q3 2025	Jan 12, 2026	-$0.09	-$0.09	+0.00%(+$0.00)
Q2 2025	Sep 10, 2025	-$0.10	-$0.07	+30.00%(+$0.03)

ANIX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.11

4.10

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ANIXAnixa Biosciences, Inc.	F	—	C	442.0x	—	100.0%	—	$2.67
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Anixa Biosciences, Inc.

Anixa Biosciences develops cancer vaccines and immunotherapies targeting major oncology indications including breast, ovarian, lung, colon, and prostate cancers. The company operates two primary therapeutic segments: cancer vaccines for treatment and prevention, and CAR-T therapies including lira-cel for ovarian cancer through subsidiary Certainty Therapeutics. Anixa's approach addresses critical unmet needs in oncology through multiple immunotherapy modalities.

ANIX Insider Transactions

BuySep 30, 2026
CATELANI MICHAEL J
Officer
Shares: 5,500Value: $15,620
BuySep 24, 2026
KUMAR AMIT
Chief Executive Officer
Shares: 7,000Value: $19,460
BuySep 24, 2026
BASKIES ARNOLD M
Director
Shares: 5,000Value: $13,800
BuySep 10, 2026
TITTERTON LEWIS H JR
Director
Shares: 10,000Value: $27,300
BuySep 10, 2026
KUMAR AMIT
Chief Executive Officer
Shares: 5,000Value: $13,800

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

CBUSCibus, Inc. Class A Common StockAgricultural Chemicals
BDTXBlack Diamond Therapeutics, Inc. Common StockBiological Products
IMDXInsight Molecular Diagnostics Inc. Common StockIn Vitro Diagnostics
ICCCImmucell CorpIn Vitro Diagnostics
ATRAAtara Biotherapeutics, IncBiological Products
NMRANeumora Therapeutics, Inc. Common StockBiological Products
TNYATenaya Therapeutics, Inc. Common StockBiological Products
GRMLGreenland Mines Ltd. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$2.32

High$5.46